Combretastatin A4

For research use only. Not for use in humans.

目录号:S7783 中文名称:康普立停 A4

Combretastatin A4 Chemical Structure

CAS No. 117048-59-6

Combretastatin A4 是一种以 microtubule 为靶点的试剂,其与β-微管蛋白结合,Kd 为 0.4 μM。Phase 3。

规格 价格 库存 购买数量  
RMB 811.66 现货
RMB 3258.32 现货
RMB 8166.98 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck生产的Combretastatin A4发表文献3篇:

产品安全说明书

Microtubule Associated抑制剂选择性比较

生物活性

产品描述 Combretastatin A4 是一种以 microtubule 为靶点的试剂,其与β-微管蛋白结合,Kd 为 0.4 μM。Phase 3。
靶点
β-tubulin [1]
0.4 μM(Kd)
体外研究

Combretastatin A4抑制MDA-MB-231,A549,Hela,HL-60,SF295,HCT-8,MDA-MB435,PC3M,OVCAR-8,NCI-H358M,和淋巴细胞的生长,IC50分别为2.8,3.8,0.9,2.1,6.2,5.3,7.9,4.7,0.37,8,和3.2 nM。[1] [2]1 μM Combretastatin A4抑制35%微管蛋白聚合,10 μM几乎完全阻断微管蛋白聚合。Combretastatin A4表现出高的相对结合能力,达到秋水仙碱结合力的78%。[1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
SKMEL-5 MWDHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NWnpeJJsS3m2b4TvfIlkKGOxbnPlcpRz[XSrb36gdoVyfWm{ZXSgeI8hcW6qaXLpeEA2OCViY3XscEBoem:5dHigbY4hW0uPRVytOUBu\Wyjbn;tZUBk\WyuIHzpcoV{NCCHREWwQVMvODCHLUC4JO69VQ>? MlzCNVg4PTN3MB?=
A-549 MnixS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MkDMR5l1d3SxeHnjJINwdmOnboTyZZRqd25icnXxeYlz\WRidH:gbY5pcWKrdDC1NEUh[2WubDDndo94fGhiaX6gRU02PDlibIXu[{Bk[XKlaX7vcYEh[2WubDDsbY5meyxiRVS1NF0yNjJyRT2wOkDPxE1? MVexPFc2OzVy
MCF-7 M{Kx[Wdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M1[zSmN6fG:2b4jpZ{Bkd26lZX70doF1cW:wIILldZVqemWmIITvJIlvcGmkaYSgOVAmKGOnbHyg[5Jwf3SqIHnuJG1ETi15IHLy[YF{fCClYYLjbY5wdWFiY3XscEBtcW6nczygSWQ2OD1|LkiwSU0xPiEQvF2= M{L4eVE5PzV|NUC=
HT-29 NEfwNVlIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MXzDfZRwfG:6aXOgZ49v[2WwdILheIlwdiC{ZYH1bZJm\CC2bzDpcohq[mm2IEWwKUBk\WyuIHfyc5d1cCCrbjDIWE0zQSClb3zvckBi\GWwb3PhdoNqdm:vYTDj[YxtKGyrbnXzMEBGTDVyPUGuNlBGNTB4IN88US=> NH;DRpUyQDd3M{Ww
MLM melanoma cell NIH5TIJIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NXfvemIyS3m2b4TvfIlkKGOxbnPlcpRz[XSrb36gdoVyfWm{ZXSgeI8hcW6qaXLpeEA2OCViY3XscEBoem:5dHigbY4hVUyPIH3lcIFvd22jIHPlcIwhdGmwZYOsJGVFPTB;MT60NGUuODZizszN Mlf5NVg4PTN3MB?=
M14 NHjtNItEgXSxdH;4bYNqfHliYYPzZZk> NFfUW4hKdiC4aYTyc{BkgXSxdH;4bYMh[WO2aY\peJkhf2G|IITld5Rm\CCjZ3HpcpN1KGi3bXHuJI1mdGGwb33hJINidmOncjCoUVE1MSClZXzsJIxqdmVuIFfJOVA:OC5yMECxJO69VQ>? NIjxT2kyOjd{OU[0NC=>
SK-OV3 NWO4U5FPS3m2b4TvfIlkcXS7IHHzd4F6 NGLmXmNKdiC4aYTyc{BkgXSxdH;4bYMh[WO2aY\peJkhfGW|dHXkJIFo[Wmwc4SgbJVu[W5ib4\hdolidiClYX7j[ZIhMFONLV;WN{kh[2WubDDsbY5mNCCJSUWwQVAvODByMTFOwG0> NGLqfmoyOjd{OU[0NC=>
HL60 cells M4XvWGN6fG:2b4jpZ4l1gSCjc4PhfS=> MWG3NkBp NUL6[HdvS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUEx4MDDj[YxteyCjZoTldkA4OiCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwQVAvODByMTFOwG0> NYToeHg5OjB5M{GzOVU>
SK-OV-3 NILrcHhIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NXvHWFl3PDhiaB?= NYizeXZtT3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hW0tvT2[tN{Bi\nSncjC0PEBpenNiYomgV3JDKGG|c3H5MEBIUTVyPUCuNFAxOTNizszN MWexPFczOjF{Nx?=
HepG2 cells M{T2R2N6fG:2b4jpZ4l1gSCjc4PhfS=> MYDDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDI[ZBIOiClZXzsd{whUUN3ME2wMlAxODF2IN88US=> M3\s[VE4OTJ5ME[x
ZR-75-1 NFfl[pVEgXSxdH;4bYNqfHliYYPzZZk> NEjrZlREgXSxdH;4bYNqfHliYXfhbY5{fCCcUj23OU0yKGOnbHygcIlv\SxiSVO1NF0xNjByMEK0JO69VQ>? MVexO|I1QTZ2OR?=
HeLa cell MV\DfZRwfG:6aXPpeJkh[XO|YYm= NXzCTpozS3m2b4TvfIlkcXS7IHHnZYlve3RiSHXMZUBk\WyuIHzpcoUtKEmFNUC9NE4xODB|IN88US=> MmPFNVczPDl4NEm=
HCT116 cell M3TUUmN6fG:2b4jpZ4l1gSCjc4PhfS=> NF3O[29EgXSxdH;4bYNqfHliYXfhbY5{fCCKQ2SxNVYh[2WubDDsbY5mNCCLQ{WwQVAvODByM{Wg{txO NVfpXG9[OTd{NEm2OFk>
KBV1 cells MVvDfZRwfG:6aXPpeJkh[XO|YYm= NH;GXW84OiCq MlPWR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6geolv[myjc4TpcoUuemW|aYP0ZY51KEuEVkGgZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KE2WVDDhd5NigSxiSVO1NF0xNjByMESg{txO MVeyNFc{OTN3NR?=
SKOV3 MnrXR5l1d3SxeHnjbZR6KGG|c3H5 NF;Oc2dEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBUU0:YMzDj[YxteyCkeTDTVmIh[XO|YYmsJGdKPTB;MD6wNFA1OiEQvF2= MUSyOFAyPjByMh?=
SKOV3 cells MmjvS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MmjZS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gV2tQXjNiY3XscJMh[nlic4Xs[o9zcG:mYX3pcoUhSiCjc4PhfUwhT0l3ME2wMlAxODR{IN88US=> Ml;iNlM4PzJ|MEm=
HeLa cells MkntR5l1d3SxeHnjbZR6KGG|c3H5 NHzuV3lEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBJ\UyjIHPlcIx{KGK7IF3UWEBie3OjeTygTWM2OD1yLkCwNFUyKM7:TR?= NGDtOlIyQTh5OUe1PC=>
DU145 cells M370ZWN6fG:2b4jpZ4l1gSCjc4PhfS=> NXz4W5Q{S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hTFVzNEWgZ4VtdHNiYomgV3JDKGG|c3H5MEBIUTVyPUCuNFAxPTRizszN M1fJXFI1ODF4MECy
DU145 cells NFi3OWJIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M{nleWdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJGRWOTR3IHPlcIx{KGK7IIP1cIZwemixZHHtbY5mKEJiYYPzZZktKEeLNUC9NE4xODB3NDFOwG0> MkWwNlM4PzJ|MEm=
SK-N-BE NGrVWZRRem:uaX\ldoF1cW:wIHHzd4F6 Ml;sO|IhcA>? NIDCRmtCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBqdiCqdX3hckBUUy2QLVLFJINmdGy|IHHzd4V{e2WmIHHzJINmdGxidnnhZoltcXS7IHHmeIVzKDd{IHjyd{BjgSCPVGSgZZN{[XluIFnDOVA:OC5yMEC1PEDPxE1? NVvDSFBTOjJ|Mkm1OlE>
NCIH460 cells MY\DfZRwfG:6aXPpeJkh[XO|YYm= NYLwVnFFPDhiaB?= M2rlU2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG5EUUh2NkCgZ4VtdHNiYX\0[ZIhPDhiaILzJIJ6KFOUQjDhd5NigSxiR1m1NF0xNjByME[g{txO MljsNVg{ODN6NEm=
KB-VIN10 cells M2LhNXBzd2yrZnXyZZRqd25iYYPzZZk> NITublE4OiCq MUTBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEuELW\JUlExKGOnbHzzJI93\XJvZYjwdoV{e2mwZzDQMYdxKDF5MD;NSHIyKGGodHXyJFczKGi{czDifUBu\XSqeXzlcoUh[my3ZTDhd5NigSxiSVO1NF0xNjByMEeg{txO M1jUeFIyPjRzN{Cw
HCT116 cells M3\rSmN6fG:2b4jpZ4l1gSCjc4PhfS=> M1m1bFczKGh? NWnET5lCS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUEOWMUG2JINmdGy|IHHzd4V{e2WmIHHzJJJm\HWldHnvckBw\iCdM1jdeIh6dWmmaX7lJIlv[2:{cH;yZZRqd25iYX\0[ZIhPzJiaILzJIJ6KHOlaX70bYxt[XSrb36gZ492dnSrbnesJGlEPTB;MD6wNFA4PCEQvF2= MX:yNVk2PTR3NB?=
DU145 cells NVrCWphVS3m2b4TvfIlkcXS7IHHzd4F6 NVTVdY1yPDhiaB?= MVXDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDEWVE1PSClZXzsd{Bi\nSncjC0PEBpenNiYomgV3JDKGG|c3H5MEBIUTVyPUCuNFAxQCEQvF2= NGSydXoyQDNyM{i0PS=>
RS4:11 cells NFe3WlRRem:uaX\ldoF1cW:wIHHzd4F6 MlvhO|IhcA>? M3K2TmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iUmO0PlEyKGOnbHzzJIFnfGW{IEeyJIhzeyCkeTCoN{0pPCx3LXTpcYV1cHmudHjpZZpwdC1{LYnsLU0zNDVvZHnwbIVvgWy2ZYTyZZpwdGm3bTDido9ucWSnIITld5QtKEmFNUC9NE4xODB6IN88US=> MYOyOVc5PTZyNR?=
HCT 116 NVvWbYpCT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MUXDc45k\W62cnH0bY9vKHeqaXPoJJBzd2S3Y3XzJFUxLSCrbnjpZol1cW:wIH;mJIdzd3e2aDDv[kBpfW2jbjDjc4xwdiC2dX3vdkBJS1RiMUG2MEBKSzVyPUCuNFAxQSEQvF2= NXmyPZRlOTF5MUS2NVM>
HeLa cells NGLxeIVEgXSxdH;4bYNqfHliYYPzZZk> MVu3NkBp M1;tN2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGhmVGFiY3XscJMh[W[2ZYKgO|IhcHK|IHL5JJJme2G8dYLpckBj[XOnZDDmcJVwemW|Y3XuZ4Uh[XO|YYmsJGlEPTB;MD6wNFA6KM7:TR?= MVGyOFY3QTh6OB?=
BNL 1ME A.7R.1 cells NXPPUodrS3m2b4TvfIlkcXS7IHHzd4F6 M2TJUWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KG2xdYPlJGJPVCBzTVWgRU44Wi5zIHPlcIx{NCCLQ{WwQVAvODByOTFOwG0> MX2yOVc5PTZyNR?=
Calu6 MWrQdo9tcW[ncnH0bY9vKGG|c3H5 M3XoN|Q5KGh? MnHVRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCFYXz1OkBi\nSncjC0PEBpenNiYomgd5Bm[3S{b4Doc5RwdWW2comsJGlEPTB;MD6wNFA6PCEQvF2= NIjyXJIzOTd5NES5PS=>
melanoma B16 cell M{HuNGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MVnDc45k\W62cnH0bY9vKHeqaXPoJJBzd2S3Y3XzJFUxLSCrbnjpZol1cW:wIH;mJIdzd3e2aDDv[kBufXKrbnWgcYVt[W6xbXGgRlE3KGOnbHygcIlv\SxiSVO1NF0xNjByMTFOwG0> NX\uWYE1OTF5MUS2NVM>
DU145 cells M{ThcmN6fG:2b4jpZ4l1gSCjc4PhfS=> M3TQSGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGRWOTR3IHPlcIx{KGK7IGPSRkBie3OjeTygS2k2OD1yLkCwNUDPxE1? M13NVlIxPDl4OUKz
HCT116 cells M1\rdXBzd2yrZnXyZZRqd25iYYPzZZk> MWe3NkBp MWPBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEiFVEGxOkBk\WyuczDh[pRmeiB5MjDodpMh[nliTWTTJIF{e2G7LDDJR|UxRTBwMECxJO69VQ>? MUGyNVEyOjF|MB?=
HCT15 cells M4DIZXBzd2yrZnXyZZRqd25iYYPzZZk> MnjCO|IhcA>? NHXYeZRCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFjDWFE2KGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDNWHMh[XO|YYmsJGlEPTB;MD6wNFEh|ryP MknFNlEyOTJzM{C=
HL60 cells NYnHWXdsWHKxbHnm[ZJifGmxbjDhd5NigQ>? NFO0dHQ4OiCq Mmn6RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCKTE[wJINmdGy|IHHzd4V{e2WmIHHzJIdzd3e2aDDpcohq[mm2aX;uJIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO|YYmsJGlEPTB;MD6wNFEh|ryP M{T6TlIyPjZ|M{G5
A10 cells NYe4dlBvT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M3T6UVQ5KGh? M2DYd2dzd3e2aDDpcohq[mm2aX;uJI9nKHKjdDDBNVAh[2WubIOgZYZ1\XJiNEigbJJ{KGK7IF3UWEBie3OjeTygTWM2OD1yLkCwNUDPxE1? NWKwO4FzOjJyNESxOlQ>
HUVEC cells MV7Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M3vlVFQ5KGh? M1nQRmdzd3e2aDDpcohq[mm2aX;uJI9nKEiXVlXDJINmdGy|IHHmeIVzKDR6IHjyd{BjgSCPVGSgZZN{[XluIFnDOVA:OC5yMEGg{txO MmPxNlIxPDRzNkS=
HL60 cells NUnleotzS3m2b4TvfIlkcXS7IHHzd4F6 MVe3NkBp MX;DfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDIUFYxKGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO|YYmsJGlEPTB;MD6wNFEh|ryP NIjreIkzOjF|NkOxNi=>
HL60 cells Mn\kVJJwdGmoZYLheIlwdiCjc4PhfS=> NESyZ2k4OiCq MmLwRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCKTE[wJINmdGy|IHHzd4V{e2WmIHHzJIdzd3e2aDDpcohq[mm2aX;uJIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO|YYmsJGlEPTB;MD6wNFEh|ryP NF34fIczOjV5OEGxNS=>
NCI-H522 cells NE\wO2xIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MVm0PEBp NUDZVmhIT3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLVi1NlIh[2WubIOgZYZ1\XJiNEigbJJ{KGK7IGPSRkBie3OjeTygS2k2OD1yLkCwNUDPxE1? M3nV[FIzQTh{MUKy
MDA-MB-435 cells M1u0fWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NEfnVnY1QCCq MkTwS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gUWRCNU2ELUSzOUBk\WyuczDh[pRmeiB2ODDodpMh[nliU2LCJIF{e2G7LDDHTVUxRTBwMECxJO69VQ>? M3rKOlIzQTh{MUKy
OVCAR3 NF3TRphIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MXm0PEBp M1fhO2dzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJG9XS0GUMzDj[YxteyCjZoTldkA1QCCqcoOgZpkhW1KEIHHzd4F6NCCJSUWwQVAvODBzIN88US=> NX7tOXdSOjJ7OEKxNlI>
NCI/ADR-RES cells NHr3e|RIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MX[0PEBp MmnCS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gUmNKN0GGUj3SSXMh[2WubIOgZYZ1\XJiNEigbJJ{KGK7IGPSRkBie3OjeTygS2k2OD1yLkCwNUDPxE1? M13INlIzQTh{MUKy
PC3 cells M{DNXGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NXS3cIdNPDhiaB?= M3P1e2dzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJHBEOyClZXzsd{Bi\nSncjC0PEBpenNiYomgV3JDKGG|c3H5MEBIUTVyPUCuNFAyKM7:TR?= NUm5TYk3OjJ7OEKxNlI>
DU145 cells NFrZ[VlIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NG\uNm01QCCq NGKxZmZIem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBFXTF2NTDj[YxteyCjZoTldkA1QCCqcoOgZpkhW1KEIHHzd4F6NCCJSUWwQVAvODBzIN88US=> NEXyRWYzOjl6MkGyNi=>
MDA-MB-231 cells M{H4O2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M3uy[FQ5KGh? MlWxS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gUWRCNU2ELUKzNUBk\WyuczDh[pRmeiB2ODDodpMh[nliU2LCJIF{e2G7LDDHTVUxRTBwMECxJO69VQ>? MWKyNlk5OjF{Mh?=
CEM cells NEjPXVhEgXSxdH;4bYNqfHliYYPzZZk> MkXjO|IhcA>? M2XmTmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGNGVSClZXzsd{Bi\nSncjC3NkBpenNiYomgUXRVKGG|c3H5MEBKSzVyPUCuNFAyKM7:TR?= NFzYd4ozOjZ5NkK0Oy=>
HCT116 cells MW\DfZRwfG:6aXPpeJkh[XO|YYm= NXniUYxSPzJiaB?= MnHuR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTGNVOTF4IHPlcIx{KGGodHXyJFczKGi{czDifUBOXFRiYYPzZZktKEmFNUC9NE4xODFizszN MX:yNlY4PjJ2Nx?=
MDA-MB-435 cells MVnDfZRwfG:6aXPpeJkh[XO|YYm= M4j3O|czKGh? MUfDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDNSGEuVUJvNEO1JINmdGy|IHHmeIVzKDd{IHjyd{BjgSCPVGSgZZN{[XluIFnDOVA:OC5yMEGg{txO M{DoVFIzPjd4MkS3
HaCaT cells MkLRVJJwdGmoZYLheIlwdiCjc4PhfS=> MlHTRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCKYVPhWEBk\WyuczDhd5Nme3OnZDDhd{Bk\WyuII\pZYJqdGm2eTDifUBOXFRiYYPzZZktKEmFNUC9NE4xODFizszN M1vzW|I{ODZ|NECx
HL60 cells NXiwd5gxWHKxbHnm[ZJifGmxbjDhd5NigQ>? NXuwdWtqPzJiaB?= MVPBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEiONkCgZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KE2WVDDhd5NigSxiSVO1NF0xNjByMTFOwG0> MX2yN|EyPzF5MR?=
HL60 cells MW\Qdo9tcW[ncnH0bY9vKGG|c3H5 MnXoO|IhcA>? NIfod|VCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFjMOlAh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IDizMUg1NDVvZHnt[ZRpgWy2aHnhfo9tNTJveXypMVItPS2maYDo[Y56dHSndILhfo9tcXWvIHLyc41q\GVidHXzeEwhUUN3ME2wMlAxOSEQvF2= M1LxPVI2Pzh3NkC1
HT-29 NYWzR25RT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NIHabXlIem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBJXC1{OTDj[YxteyCkeTDNWHQh[XO|YYmsJGlEPTB;MD6wNFEh|ryP MW[yOVY5QTFzMR?=
HL60 cells M3jGZXBzd2yrZnXyZZRqd25iYYPzZZk> NGXDV|Y4OiCq NEm2TVZCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFjMOlAh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IF3UWEBie3OjeTygTWM2OD1yLkCwNUDPxE1? M36xZ|IxPDJyNEO5
Hs578T cells NIqwe|JIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M{HaVVQ5KGh? MY\Hdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDId|U4QFRiY3XscJMh[W[2ZYKgOFghcHK|IHL5JHNTSiCjc4PhfUwhT0l3ME2wMlAxOSEQvF2= MUSyNlk5OjF{Mh?=
HL60 cells MmntR5l1d3SxeHnjbZR6KGG|c3H5 NX7zNYppPzJiaB?= NYjqPWNvS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUEx4MDDj[YxteyCjZoTldkA4OiCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwQVAvODBzIN88US=> NYSzd41bOjN2NEW0PVY>
SKOV3 cells MXzHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M3y4XWdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJHNMV1Z|IHPlcIx{KGK7IF3UWEBie3OjeTygTWM2OD1yLkCwNUDPxE1? MnjJNlU3QDlzMUG=
MDA-MB-468 cells NEK3W|VEgXSxdH;4bYNqfHliYYPzZZk> Mm\lOEBl[Xm| M3i4TGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG1FSS2PQj20Olgh[2WubIOgZZN{\XO|ZXSgZZMh[2WubDD2bYFjcWyrdImgZYZ1\XJiNDDkZZl{KGK7IF3UV{Bie3OjeTygTWM2OD1yLkCwNVEh|ryP NUTlNXZEOjR{MUC1NFM>
MCF7 cells MYfQdo9tcW[ncnH0bY9vKGG|c3H5 MVW3NkBp NF7GRo1CdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBqdiCqdX3hckBOS0Z5IHPlcIx{KGG|c3Xzd4VlKGG|IHPlcIwhfmmjYnnsbZR6KGGodHXyJFczKGi{czDifUBOXFRiYYPzZZktKEmFNUC9NE4xODFzMTFOwG0> MXGyNlMzQTV4MR?=
H460 Ml;vR5l1d3SxeHnjbZR6KGG|c3H5 Ml\nR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTFQ3OCClZXzsd{BjgSC|dXzmc5Jpd2SjbXnu[UBDKHSnc4SsJGlEPTB;MD6wNFEzKM7:TR?= NXnmUJdEOTh5OEOyNFc>
H460 NGHqS4FRem:uaX\ldoF1cW:wIHHzd4F6 NHnyXoFCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFi0OlAh[2WubIOsJGlEPTB;MD6wNFEzPCEQvF2= MV:xOlczOjZ|Mx?=
NCI-H460 cells NFHQfGtEgXSxdH;4bYNqfHliYYPzZZk> MXO3NkBp M4SyUGN6fG:2b4jpZ{Bi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF7DTU1JPDZyIHPlcIx{KGGodHXyJFczKGi{czDifUB{fWyob4Loc4RidWmwZTDCJJRme3RuIFnDOVA:OC5yMEGzJO69VQ>? NX;3WIRjOTh|OU[4OVc>
OVCAR8 cells NYLtdIFvT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M{n2WVk3KGh? M2LvW2dzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJG9XS0GUODDj[YxteyCxdnXy[ZhxemW|c3nu[{BRNWeueXPvdJJwfGWrbjDh[pRmeiB7NjDodpMtKEmFNUC9NE4xODF|IN88US=> M{LCcVIzODR2MU[0
NCI/ADR-RES cells MXrDfZRwfG:6aXPpeJkh[XO|YYm= NFXVW4ZEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBPS0lxQVTSMXJGWyClZXzsd{Bie3Onc4Pl[EBieyCpcn;3eIghcW6qaXLpeIlwdiCkeTD0dplx[W5iYnz1[UBmgGOudYPpc44h[XO|YYmsJGlEPTB;MD6wNFE{KM7:TR?= M4nnelI{OjF2NEWy
OVCAR8 cells M2LtcmN6fG:2b4jpZ4l1gSCjc4PhfS=> NEHs[Fc6PiCq MlO1R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gU3ZESVJ6IHPlcIx{KGG|c3Xzd4VlKGG|IHfyc5d1cCCrbnjpZol1cW:wIHHmeIVzKDl4IHjyd{BjgSCJaXXtd4Ehe3SjaX7pcocu[mG|ZXSgcIlocHRibXnjdo9{[2:yeTygTWM2OD1yLkCwNVMh|ryP M3ryNVI2ODJ3OUmx
NCI/ADR-RES cells NV20Vml[S3m2b4TvfIlkcXS7IHHzd4F6 NFTLb5o6PiCq NH\ac2FEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBPS0lxQVTSMXJGWyClZXzsd{Bie3Onc4Pl[EBieyCpcn;3eIghcW6qaXLpeIlwdiCjZoTldkA6PiCqcoOgZpkhT2mnbYPhJJN1[WmwaX7nMYJie2WmIHzp[4h1KG2rY4Lvd4NweHluIFnDOVA:OC5yMEGzJO69VQ>? NU[3ZVBzOjVyMkW5PVE>
OVCAR8 cells MV\DfZRwfG:6aXPpeJkh[XO|YYm= NWCyRVZFS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hV1[FQWK4JINmdGy|IHHzd4V{e2WmIHHzJIdzd3e2aDDpcohq[mm2aX;uJIJ6KHS{eYDhckBjdHWnIHX4Z4x2e2mxbjDhd5NigSxiSVO1NF0xNjByMUOg{txO M4TUN|I{OjF2NEWy
HuTu 80 cells NEPjeo9Rem:uaX\ldoF1cW:wIHHzd4F6 NXe0c3V6PzJiaB?= M1jMfGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIlvKGi3bXHuJGh2XHViOECgZ4VtdHNiYYPz[ZN{\WRiYYOgZ4VtdCC4aXHibYxqfHliYX\0[ZIhPzJiaILzJIJ6KE2WVDDhd5NigSxiSVO1NF0xNjByMUO3JO69VQ>? NHLkSZUzOjN{OUW2NS=>
K562 cells M3HofGN6fG:2b4jpZ4l1gSCjc4PhfS=> NVPhSoxyS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUzV4MjDj[YxteyxiSVO1NF0xNjByMUSg{txO M3riOVE6QDN5NUm0
NCI/ADR (MDR) cells Mk\XSpVv[3Srb36gZZN{[Xl? NFr5SW9E\WyuIHP5Z4xmKGG{cnXzeEBqdiCQQ1mvRWRTKCiPRGKpJINmdGy|IHL5JIFk[3WvdXzheIlwdiCjdDDHNk9OKHCqYYPlMEBKSzVyPUCuNFAyPSEQvF2= NY\YSVBIOTZ|N{exPFc>
HUVEC NIni[GZRem:uaX\ldoF1cW:wIHHzd4F6 NX6we5FXSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDIWXZGSyxiSVO1NF0xNjByMUWg{txO MYSxOlczOjZ|Mx?=
KB cell MlvoVJJwdGmoZYLheIlwdiCjc4PhfS=> MYPBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEuEIHPlcIwhdGmwZTDifUBu\XSqeXzlcoUh[my3ZTDkfYUh[XO|YYmsJGlEPTB;MD6wNFE2KM7:TR?= M3zNZlE4ODN2MUS3
KB-VIN10 cell MmfSVJJwdGmoZYLheIlwdiCjc4PhfS=> NV25VWhjSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDLRk1XUU5zMDDj[YxtKGyrbnWgZpkhdWW2aIns[Y5mKGKudXWg[JlmKGG|c3H5MEBKSzVyPUCuNFAyPSEQvF2= NIK1[XoyPzB|NEG0Oy=>
Human SH-SY5Y neuroblastoma cells M{\oRWZ2dmO2aX;uJIF{e2G7 NVuxc203UW6qaXLpeI9zgSClb37j[Y51emG2aX;uJIFo[Wmwc4SgTJVu[W5iU1itV3k2YSCwZYXyc4Jt[XO2b33hJINmdGy|LDDJR|UxRTBwMECxOUDPxE1? NFLlfoMyPTl4M{eyNi=>
SW620 cells M1XPO3Bzd2yrZnXyZZRqd25iYYPzZZk> MoXxO|IhcA>? M1LHNmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIlvKGi3bXHuJHNYPjJyIHPlcIx{KGG|c3Xzd4VlKGG|IHPlcIwhfmmjYnnsbZR6KGGodHXyJFczKGi{czDifUBOXFRiYYPzZZktKEmFNUC9NE4xODF3MjFOwG0> MUKyNlMzQTV4MR?=
Molt4/C8 cells M1yzNHBzd2yrZnXyZZRqd25iYYPzZZk> MVPBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE2xbIS0M2M5KGOnbHzzMEBKSzVyPUCuNFAyPiEQvF2= NGXv[2EyPzB|NEG1NC=>
ACHN cell MmHIVJJwdGmoZYLheIlwdiCjc4PhfS=> Mn3sRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDkdpVoKHKnc3nzeIFvfCCDQ1jOJINmdGxibHnu[UBmgHC{ZYPzbY5oKE2GUkGgZpkhSWyjbXHyJGJtfWViYYPzZZktKEmFNUC9NE4xODF4IN88US=> NVjwPZRHOTd{OE[zPVM>
Molt4/C8 cells M4DmTXBzd2yrZnXyZZRqd25iYYPzZZk> NWPTVm8zOyCmYYnz MXHBcpRqeHKxbHnm[ZJifGm4ZTDl[oZm[3RiYXfhbY5{fCCqdX3hckBOd2y2ND;DPEBk\WyuczDh[pRmeiB|IHThfZMtKEmFNUC9NE4xODF4IN88US=> NXTyVY1tOTd2MUm2NFc>

... Click to View More Cell Line Experimental Data

体内研究 在NT2和MDA-MB-231乳腺肿瘤模型中,Combretastatin A4 (100 mg/kg, i.p.)诱导脂质R1显著减少,并通过电子顺磁共振(EPR)血氧定量法测得pO2下降。[2] Combretastatin A4 (100 mg/kg, i.p.)显著减少雄性NMRI小鼠的Ktrans[3]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验:[1]
- 合并

使用 LC-MS/MS 的竞争性结合试验:

Colchicine (1.2 μ M)与微管蛋白(1.3 mg/mL)在培养缓冲液(80 mM PIPES,2.0 mM MgCl2,0.5 mM EGTA,pH 6.9)中于37℃下培养1小时。使用不同浓度(0.1− 125 μ M)的Combretastatin A4与原本结合微管蛋白的colchicine竞争。培育后,得到滤液。类似物抑制秋水仙碱结合的能力表示为不存在任何竞争物的对照组的百分比。
细胞实验:[1]
- 合并
  • Cell lines: MDA-MB-231,A549,和 Hela 细胞
  • Concentrations: ~3.8 nM
  • Incubation Time: 72 h
  • Method: MDA-MB-231,A549,和HeLa细胞在DMEM培养基(115 units/mL 青霉素G,115 μg/mL 链霉素,和10%胎牛血清)中生长。细胞(5000 细胞/孔)接种于包含50 μL生长培养基的96孔板,培养24小时。移除培养基后,将100 μL包含不同浓度单个类似化合物的新鲜培养基加入到每个孔中,在37 ℃下培养72小时。培养24小时后,细胞中增补50 μL溶于DMSO(每个制剂中少于0.25%)的类似化合物。培养72小时后,加入20 μL刃天青培养2小时,然后在560 nm (激发波长)和590 nm (发射波长)下使用Victor微量滴定板荧光剂记录荧光。对照组为用最大量DMSO (0.25%)处理的细胞,活性为100%,IC50定义为与对照组相比,抑制50%细胞增殖的化合物浓度。
    (Only for Reference)
动物实验:[2]
- 合并
  • Animal Models: 负荷 NT2 和 MDA-MB-231肿瘤的 FVB/N或裸的NMRI雄性小鼠
  • Dosages: 100 mg/kg
  • Administration: i.p.
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 63 mg/mL (199.14 mM)
Ethanol 34 mg/mL warmed (107.47 mM)
Water Insoluble
体内 从左到右依次将纯溶剂加入产品,现配现用(数据来自Selleck实验检测而非文献):
5% DMSO+50% PEG 300+ddH2O
30mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 316.35
化学式

C18H20O5

CAS号 117048-59-6
储存条件 粉状
溶于溶剂
别名 N/A

动物体内配方计算器 (澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 ul 动物数量
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)
% DMSO % % Tween 80 % ddH2O
计算重置

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、SDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、SDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

常见问题及建议解决方法

  • 问题 1:

    How to make solution for in vivo IP injection?

  • 回答:

    We've tested some vehicles for S7783 Combretastatin A4, and found it can be dissolved in 5% DMSO+50% PEG 300+ddH2O at 30mg/ml clearly. When prepare the solution, please dissolve the compound in DMSO clearly first. The add PEG, after they mixed well, then dilute with water.

免费分装抑制剂

Microtubule Associated Signaling Pathway Map

相关Microtubule Associated产品

Tags: 购买Combretastatin A4 | Combretastatin A4供应商 | 采购Combretastatin A4 | Combretastatin A4价格 | Combretastatin A4生产 | 订购Combretastatin A4 | Combretastatin A4代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID